A Phase 4 interventional study of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus and Inadequate Glycaemic Control, sponsored by AstraZeneca. Completed at 173 sites in 5 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 15 that started in 2015, is one of 77 in phase 4, and was the 62nd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 15 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 939 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 34th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2015, is one of 28 in phase 4, and was the 249th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea) as an addition to metformin treatment.
Inclusion Criteria: Main Inclusion Criteria:
Main, Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
Drug: Dapagliflozin · Drug: Placebo for saxagliptin · Drug: Placebo for glimepiride
Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
Drug: Dapagliflozin · Drug: Saxagliptin · Drug: Placebo for glimepiride
Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
Drug: Glimepiride · Drug: Placebo for dapagliflozin · Drug: Placebo for saxagliptin
10 mg, orally Green, plain, diamond-shaped, film-coated tablet
Also known as: Forxiga
5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
Also known as: Onglyza™
1, 2, or 4 mg, orally Opaque gray capsule
Also known as: Amaryl
Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
Does not contain active ingredient, orally. Opaque gray capsule
Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52
Change in HbA1c from baseline (week 0) to week 52.
Time frame: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Patients With at Least One Episode of Confirmed Hypoglycaemia
Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose \<=50 mg/dL) during the double-blind treatment period
Time frame: Up to Week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Change in Total Body Weight From Baseline at Week 52
Change in body weight from baseline (week 0) to week 52
Time frame: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
Change in FPG from baseline (week 0) to week 52
Time frame: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Time to Rescue
The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period
Time frame: Over the 52 week treatment period
Number of Patients Rescued
Number (%) of patients rescued.
Time frame: Over the 52 week treatment period
| Milestone | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Started | 314 | 312 | 313 |
| Completed | 281 | 298 | 288 |
| Not completed | 33 | 14 | 25 |
| Withdrew: Adverse event | 7 | 1 | 2 |
| Withdrew: Developed study withdrawal criteria | 4 | 1 | 2 |
| Withdrew: Failure to meet randomization criteria | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 | 5 |
| Withdrew: Other reasons not specified | 10 | 7 | 12 |
Change in HbA1c from baseline (week 0) to week 52.
| HbA1c % | Dapaglifozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52 | -0.82 ± 0.049 | -1.2 ± 0.046 | -0.99 ± 0.048 |
Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose \<=50 mg/dL) during the double-blind treatment period
| Percentage of participants | Dapaglifozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Patients With at Least One Episode of Confirmed Hypoglycaemia | 0 | 0.32 | 4.21 |
Change in body weight from baseline (week 0) to week 52
| Weight (kg) | Dapaglifozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Change in Total Body Weight From Baseline at Week 52 | -3.54 ± 0.231 | -3.15 ± 0.219 | 1.76 ± 0.224 |
Change in FPG from baseline (week 0) to week 52
| FPG (mmol/L) | Dapaglifozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52 | -1.62 ± 0.106 | -2.08 ± 0.100 | -1.49 ± 0.105 |
The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period
| Weeks | Dapaglifozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Time to Rescue | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Number (%) of patients rescued.
| Percentage of participants | Dapaglifozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Number of Patients Rescued | 18.6 | 8.3 | 21.4 |
Collected over Adverse Events from signature of informed consent, enrolment, randomisation and throughout the 52 week treatment period and including the follow-up period. Serious Adverse Events from the time of informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin 10mg | 0/313 (0%) | 39/313 (12.5%) | 29/313 (9.3%) |
| Saxagliptin 5mg and Dapagliflozin 10mg | 0/312 (0%) | 22/312 (7.1%) | 31/312 (9.9%) |
| Glimepiride 1mg/2mg/4mg | 0/312 (0%) | 35/312 (11.2%) | 37/312 (11.9%) |
| Event | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/313 | 3/312 | 2/312 |
| Atrial fibrillationCardiac disorders | 0/313 | 0/312 | 2/312 |
| CholecystitisHepatobiliary disorders | 0/313 | 0/312 | 2/312 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 2/313 | 2/312 | 2/312 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/313 | 1/312 | 2/312 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/313 | 0/312 | 2/312 |
| Cerebrovascular accidentNervous system disorders | 2/313 | 0/312 | 0/312 |
| Urethral stenosisRenal and urinary disorders | 2/313 | 0/312 | 0/312 |
| Acute coronary syndromeCardiac disorders | 0/313 | 0/312 | 1/312 |
| Acute myocardial infarctionCardiac disorders | 0/313 | 1/312 | 0/312 |
| Event | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 29/313 | 31/312 | 37/312 |
| Age, Continuous(Years) | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg | Total |
|---|---|---|---|---|
| Mean | 57.4 ± 9.36 | 59.2 ± 7.87 | 58.6 ± 8.38 | 58.4 ± 8.58 |
| Age, Customized(Participants) | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg | Total |
|---|---|---|---|---|
| <65 | 232 | 226 | 226 | 684 |
| >=65-<75 | 81 | 86 | 85 | 252 |
| >=75 | 1 | 0 | 2 | 3 |
| Sex: Female, Male(Participants) | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg | Total |
|---|---|---|---|---|
| Female | 112 | 122 | 105 | 339 |
| Male | 202 | 190 | 208 | 600 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin 10mg | Saxagliptin 5mg and Dapagliflozin 10mg | Glimepiride 1mg/2mg/4mg | Total |
|---|---|---|---|---|
| Asian | 1 | 3 | 0 | 4 |
| Black Or African American | 2 | 2 | 2 | 6 |
| White | 311 | 307 | 311 | 929 |
Showing the first 100 of 173 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Mar 2017, 17 months.
Results were first posted in Mar 2019, 2 years after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 17 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Saxagliptin · Glimepiride